Research Options:

Week of Expected Pricing 9/16/2024
Company Name KAIROS PHARMA LTD
Proposed Ticker KAPA
CUSIP 48301N104
Business Description We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma. We are driven by innovative science to develop novel and transformative drug therapies to treat cancer.
Lead Underwriter Boustead Securities, LLC, EF Hutton LLC
Co-Managers N/A
Initial Shares 1,550,000
Revised Initial Shares N/A
Initial Price $4.00-$4.00
Revised Price N/A
Final Price $4.00
Final Ticker KAPA

 

 

   
  © 2024 ICE Data Services. All rights reserved.